In all likelihood, the Covid-19 opportunity has passed for Inovio Phamaceuticals (INO). The DNA vaccine specialist was one of the early pacesetters last year in the race to get a coronavirus vaccine to market. However, while several peers made it past the finish line a while ago, Inovio’s program has stalled, beset by issues impeding its progress. That said, Jefferies analyst Kelechi Chikere thinks the company could potentially have a lot to offer and might be worth investors’ attention. “INO has a large pipeline of over 15 different programs for infectious diseases (e.g., COVID-19 and MERs) and oncology (e.g., HPV+ cancers),” the analyst said.
https://www.tipranks.com/news/article/inovio-has-a-great-pipeline-but-is-its-stock-a-buy
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Inovio Pharmaceuticals Charts.
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Inovio Pharmaceuticals Charts.